» Articles » PMID: 39091356

Impact of Hypertensive Heart Disease, Risk Factors, and Age-period-cohort Models Across 204 Nations and Regions from 1990 to 2019: a Global Perspective from the 2019 Global Burden of Disease Study

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hypertensive heart disease (HHD) is a major global public health issue resulting from hypertension-induced end-organ damage. The aim of this study was to examine the global impact, risk factors, and age-period-cohort (APC) model of HHD from 1990 to 2019.

Methods: Data from the 2019 Global Burden of Disease were used to assess age-adjusted HHD prevalence, disability-adjusted life years (DALYs), mortality rates, and contributions of HHD risk factors with 95% uncertainty intervals (UIs). APC models were used to analyze global age, period, and cohort mortality trends for HHD.

Results: In 2019, 18.6 million prevalent HHD cases led to 1.16 million fatalities and 21.51 million DALYs. Age-adjusted rates were 233.8 (95%UI = 170.5-312.9) per 100,000 individuals for prevalence, 15.2 (11.2-16.7) for mortality, and 268.2 (204.6-298.1) for DALYs. Regionally, the Cook Islands (703.1), Jordan (561.6), and Kuwait (514.9) had the highest age-standardized incidence of HHD in 2019. There were significant increases in HHD prevalence in Andean Latin America (16.7%), western sub-Saharan Africa (5.6%), and eastern sub-Saharan Africa (4.6%). Mortality rate varied widely among countries. Risk factors like elevated systolic blood pressure and high body mass index significant influenced DALY rates, especially in females. The APC model revealed an association between mortality rates and age, with a decreasing mortality risk over time and improved survival rates for a later birth cohort.

Conclusions: Despite the reduction in prevalence, HHD remains a significant public health issue, particularly in nations with low sociodemographic indices. To alleviate the impact of HHD, prevention efforts should concentrate on the management of hypertension, weight loss, and lifestyle improvement.

Citing Articles

The Intersection between Frailty, Diabetes, and Hypertension: The Critical Role of Community Geriatricians and Pharmacists in Deprescribing.

Dinarvand D, Panthakey J, Heidari A, Hassan A, Ahmed M J Pers Med. 2024; 14(9).

PMID: 39338179 PMC: 11433409. DOI: 10.3390/jpm14090924.

References
1.
. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304):957-980. PMC: 8446938. DOI: 10.1016/S0140-6736(21)01330-1. View

2.
Mitchell J, Ventura H, Mehra M . Early recognition and treatment of hypertensive heart disease. Curr Opin Cardiol. 2005; 20(4):282-9. DOI: 10.1097/01.hco.0000168533.76966.49. View

3.
Mills K, Stefanescu A, He J . The global epidemiology of hypertension. Nat Rev Nephrol. 2020; 16(4):223-237. PMC: 7998524. DOI: 10.1038/s41581-019-0244-2. View

4.
Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala S, Alhabib K . Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. Lancet Glob Health. 2019; 7(6):e748-e760. DOI: 10.1016/S2214-109X(19)30045-2. View

5.
Musaiger A . Overweight and obesity in eastern mediterranean region: prevalence and possible causes. J Obes. 2011; 2011:407237. PMC: 3175401. DOI: 10.1155/2011/407237. View